MENS - Jyong Biotech Ltd.

QQQ $ 611.70 $ 5.09 (0.84 %)

DIA $ 467.20 $ 1.51 (0.32 %)

SPY $ 672.21 $ 3.96 (0.59 %)

TLT $ 91.38 $ -0.63 (-0.68 %)

GLD $ 378.90 $ 1.51 (0.4 %)

Previous Close

$ 60.55

Open

$ 59.30

Bid

$ 43.33 x 2

Ask

$ 62.01 x 10

Day's Range

$ 59.01 - $ 63.00

52 Week Range

$ 6.01 - $ 67.00

Volume

462,116

Average Volume

Market Cap

Beta (5Y Monthly)

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na (nm)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Trump Sparks A 2025 IPO Boom: 5 New Stocks...
10/07/2025 20:09:41

Trump's second term is fueling an IPO comeback, with 2025 listings up 50% and five stocks already soaring over 400% post-de...

12 Health Care Stocks Moving In Wednesday'...
10/01/2025 17:06:01

12 Health Care Stocks Moving In Monday's I...
09/22/2025 17:06:11

12 Health Care Stocks Moving In Monday's I...
08/11/2025 17:06:46

12 Health Care Stocks Moving In Thursday's...
07/31/2025 17:08:07

12 Health Care Stocks Moving In Thursday's...
07/03/2025 17:07:08

why-thumzup-media-shares-are-trading-higher-by-over-20-here-are-20-stocks-moving-premarket

Why Thumzup Media Shares Are Trading Highe...
07/01/2025 09:23:55

Jyong Biotech Shares Halted On Circuit Bre...
06/17/2025 15:21:55

Jyong Biotech Shares Resume Trade
06/17/2025 15:20:56

Jyong Biotech Shares Halted On Circuit Bre...
06/17/2025 15:11:28

Jyong Biotech IPO Opens For Trade At $15/S...
06/17/2025 15:11:08

Jyong Biotech IPO Quoting $12.05/Share On ...
06/17/2025 15:05:58

Trading Halt: Halt status updated at 11:00...
06/17/2025 15:00:10

Reported Earlier, Taiwan-Based Jyong Biote...
06/17/2025 06:04:32

The net proceeds from the Offering will be used for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new dr...